| Market Cap | $143.14M-53.2% |
| Revenue (ttm) | $46.39M |
| Net Income | -$26.25M |
| EPS | -$0.41 |
| Shares Out | 61.70M |
| PE Ratio | n/a |
| Forward PE | -9.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 539,262 |
| Open | $2.19 |
| Previous Close | $2.17 |
| Day's Range | $2.19 - $2.37 |
| 52-Week Range | $2.17 - $7.95 |
| Beta | 0.51 |
| Analysts | Strong Buy |
| Price Target | $7.80(+236.21%) |
| Earnings Date | Nov 10, 2026 |
About TLSI
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
TriSalus Life Sciences, Inc. Stock Analysis — InsiderScore
TriSalus Life Sciences, Inc. scored higher than 46% of companies evaluated by InsiderBuying, and ranked 34th out of 57 stocks in the healthcare sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at TriSalus Life Sciences, Inc. bought $294.2K of stock across 4 purchases in the last 90 days, the largest of them $112.0K.
The average purchase added about 13% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating TLSI in the last 3 months, one vote each. Issuer-paid research is not counted.
$TLSI stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TLSI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TLSI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TLSI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TLSI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TLSI from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from TLSI’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 revenue miss and guidance reset dominated coverage, offsetting modest 11.3% revenue growth; analyst fair value assessments turned negative.
Recent Insider Activity
Insider Score Trend Over Time
+13.2 since Nov 16Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
